Cell-Engineered Recombinant α-Synuclein: A Gage R&R Validated Protocol

Area of Science:

• Biochemistry
• Neuroscience
• Biotechnology

Background:

• Alpha-synuclein (α-Syn) misfolding and Lewy bodies are hallmarks of Parkinson's disease (PD).
• Current methods for producing α-Syn protein and fibrils (PFFs) for research are inconsistent, leading to variable and contradictory findings.
• High costs and variability in recombinant α-Syn (r α-Syn) purification hinder Parkinson's disease research.

Purpose of the Study:

• To develop a novel, rapid, low-cost, and highly reproducible method for expressing and purifying recombinant α-Syn (r α-Syn).
• To establish reliable in vitro and in vivo models for Parkinson's disease research.
• To validate the reproducibility and repeatability of the novel purification protocol using Gage R&R.

Main Methods:

• Utilized a high-cell-density expression system for overexpressing r α-Syn in BL21(DE3) cells.
• Devised a simple, high-throughput, non-chromatographical purification protocol for r α-Syn.
• Employed a crossover experimental design and orthogonal analytical methods for protein characterization and validation.

Main Results:

• The novel method successfully produced r α-Syn with minimal batch-to-batch variability.
• Gage R&R analysis validated high reproducibility and repeatability of the purification protocol.
• Orthogonal analytical methods confirmed high similarity among isolated r α-Syn batches.

Conclusions:

• The developed method provides a consistent and reliable source of r α-Syn for Parkinson's disease research.
• This approach significantly reduces variability, enabling more conclusive findings in PD studies.
• The cost-effective and high-throughput protocol facilitates the development of robust in vitro and in vivo PD models.